Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure the availability of (a) Levetiracetam and (b) other medications in the supply chain.

The Department is aware that some manufacturers of levetiracetam tablets are facing supply issues. However, alternative suppliers can fully support the market during this time.

Medicine supply chains are complex, global, and highly regulated, and there are a number of reasons why supply can be disrupted, many of which are not specific to the United Kingdom and outside of Government control, including manufacturing difficulties, access to raw materials, sudden demand spikes or distribution issues, and regulatory issues. There are approximately 14,000 licensed medicines, and the overwhelming majority are in good supply.

While we can’t always prevent supply issues from occurring, we have a range of well-established processes and tools to manage them when they arise, to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on issues to healthcare professionals including pharmacists, so they can advise and support their patients.